Evidence map›Paper›PMID 33305074›Full record

ArticleAdvances in radiation oncology

Factors Associated With Radiation Pneumonitis in Patients Receiving Electron Boost Radiation for Breast-Conserving Therapy: A Retrospective Review.

Wataru Kawakami, Shigeyuki Takamatsu, Masashi Taka, Kaname Ishii, Tetsu Nakaichi, Kazuaki Funamoto, Kunihiko Yokoyama

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Radiation pneumonitis in relation to pulmonary function, dosimetric factors, TGFβ1 expression, and quality of life in breast cancer patients receiving post-operative radiotherapy: a prospective 6-month follow-up study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  3. The Impact of PMIn vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wataru KawakamiDepartment of Radiation Oncology, Public Central Hospital of Matto Ishikawa, Ishikawa, Japan.
Shigeyuki TakamatsuDepartment of Radiation Oncology, Public Central Hospital of Matto Ishikawa, Ishikawa, Japan.
Masashi TakaDepartment of Radiation Oncology, Kanazawa University Hospital, Ishikawa, Japan.
Kaname IshiiDepartment of Surgery, Public Central Hospital of Matto Ishikawa, Ishikawa, Japan.
Tetsu NakaichiDepartment of Radiation Oncology, Public Central Hospital of Matto Ishikawa, Ishikawa, Japan.
Kazuaki FunamotoDepartment of Radiation Oncology, Public Central Hospital of Matto Ishikawa, Ishikawa, Japan.
Kunihiko YokoyamaPET Imaging Center, Public Central Hospital of Matto Ishikawa, Ishikawa, Japan.
Public Central Hospital of Matto Ishikawa · JPKanazawa University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to investigate risk factors for radiation pneumonitis (RP) caused by electron beam (EB) boost irradiation during breast-conserving therapy. METHODS AND MATERIALS: This single-institution retrospective study included patients with breast cancer treated with breast-conserving therapy from 2013 to 2019. Radiation therapy comprised whole-breast irradiation with a dose of 50 Gy and 10 Gy EB boost dose to the tumor bed. EB energies were 4, 6, 9, 12, and 15 MeV. The lung volume receiving ≥1.25 Gy (V1.25) was calculated and considered because the EB energies have a short range. All patients underwent computed tomography and positron emission tomography/computed tomography within 1 year of irradiation. Imaging evaluation was based on the Common Terminology Criteria for Adverse Events, version 5.0.

resultsOverall, 105 patients (median age, 62 years; range, 33-85) were included for analysis with a median follow-up period of 5 months. Average area of EB boost irradiation was 72 cm

conclusionsCLD of ≥1.8 cm, EB energy of ≥12 MeV, and V1.25 of ≥24 cm

Identifiers

PMID33305074
PMCPMC7718517
OpenAlexW3094270674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.